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Central nervous system metastases from nasopharyngeal carcinoma (NPC) are uncommon. The patient presented was diagnosed
withaggressiveadvancedNPCresistanttotreatmentandcomplicatedbyasolitarybrainmetastasis.APubMeddatabasesearchwas
conducted to review the existing literature regarding brain metastases of NPC, using the search terms “nasopharyngeal neoplasia,”
“nasopharyngeal carcinoma,” “nasopharynx,” “radiotherapy,” “central nervous system,” and “brain” in section of “Title/Abstract.”
The articles were ﬁrst evaluated by title and then by abstract, and thereafter appropriate manuscripts were evaluated by full text.
References of the published papers were also reviewed.
1.Introduction
Nasopharyngeal carcinoma (NPC) is a rare malignancy with
an incidence of 0.5–2 per 100,000 in Europe and the
United States [1]. In certain places such as southern China
and southeast Asia, the incidence rises signiﬁcantly and
these areas are considered endemic for NPC. Intermediate
incidence rates are found in the Mediterranean Basin and the
Arctic[1–3].InMalaysia,NPCisthemostcommonheadand
neck cancer and is second only to lung cancer among men
[4].
Itisimperativetorememberthatalthoughsquamouscell
carcinoma is the most common histological subtype of naso-
pharynx malignancy, it diﬀers from other head and neck
squamous cell carcinomas in epidemiology, etiology, histo-
logy, natural history, and response to treatment [1–4]. Eti-
ology is multifactorially inﬂuenced by host of viral, genetic,
and environmental contributors [5]. Epstein-Barr virus
(EBV) infection was found to be a major contributor in
the pathogenesis of NPC in both endemic and nonendemic
areas and is ubiquitous in NPC, as the malignant cells con-
tain multiple copies of the EBV genome regardless of his-
tology or diﬀerentiation [5].
Symptoms of NPC can be obscure due to its anatomic
location which begins in upper part of the pharynx behind
the nose and ends at the proximal part of the trachea and
esophagus. These include nasal, aural, and neurologic symp-
toms, thus often a challenge in diagnosis. Cervical lym-
phadenopathy is commonly noted in physical examination
as the majority of newly diagnosed NPC patients have locor-
egionally advanced disease, and cervical nodes are usually
involved [5]. More than 13% of the patients are presented
with occult primary tumors.
Treatmentisusuallycomposedofanonsurgicalapproach
as the anatomic location is diﬃcult to manage and in most
cases there is a locoregional disease; therefore, currently the
standard of care for these patients consists of concurrent
chemoradiotherapy with cisplatin-based regimens, generally
followed by adjuvant chemotherapy [5]. This treatment ap-
proach results in cure for the vast majority of patients, with
3-year disease-free and overall survival rates of approxi-
mately70%and80%,respectively.Surgeryisusuallyreserved
for persistent or recurrent disease [5].
Itiswidelyknownthat,althoughNPCcandirectlyinvade
the skull base, true brain metastases of NPC are rare. The
most common sites for distant NPC metastases are the bone,
lung,andliver.APubMeddatabasesearchofexistingEnglish
literature regarding brain metastases of NPC revealed few
well-describedcases.Otherreports of centralnervous system
(CNS) involvement describe spinal or pituitary metastases.2 Case Reports in Medicine
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Figure 1: A Brain MRI showed a single occipital brain lesion.
A case of aggressive NPC with a solitary brain metastasis and
related literature is discussed.
2.CaseReport
A54-year-oldmalepatient,JewishCaucasianIsraeliofNorth
African descent, no history of chronic disease, no history
of ethanol abuse or smoking. For 6 months prior to being
diagnosed, the patient complained of tinnitus of left ear and
hearing loss. The patient was referred by his family doctor
to brain CT scan, which revealed an asymmetry at the left
nasopharynx and no evidence of brain lesion. ENT evalua-
tion included ﬁberoptic endoscopy, which indicated a bulb
in the left nasopharynx. Biopsy was positive for poorly dif-
ferentiated nasopharyngeal carcinoma. Fluorodeoxyglucose
positron emission computed tomography (FDG-PET/CT)
scan prior to treatment showed pathological uptakes at the
leftnasopharynxandleftlevelIIlymphnodes.Brainandcer-
vical MRI did not show any skull base involvement or brain
metastases.ThepatientwasdiagnosedwithT3N1M0(AJCC,
7th edition) poorly diﬀerentiated NPC. Thereafter, he re-
ceived one cycle of induction chemotherapy (according to
our department protocol) with cisplatin (100mg/m2,d a y1 )
and 5-ﬂuorouracil (1000mg/m2,d a y s1 – 5 ) .T h eﬁ f t hd a yo f
5-ﬂuorouracil was omitted due to acute renal failure, which
resolved with conservative treatment. One month later,
chemoradiotherapy was initiated using intensity-modulated
radiation therapy: a total dose of 70Gy to the tumor site
and involved lymph node and 50Gy to bilateral neck ﬁelds
(all levels, excluding level Ia), concomitant with weekly
carboplatin(areaunderthecurve(AUC)of2).FDG-PET/CT
scan performed three months after completion of chemo-
radiotherapy showed pathological uptakes in the left cervical
lymph nodes and several uptakes in the lung that were
suspicious for metastases. A biopsy taken from a lung lesion
was positive for metastatic NPC. Chemotherapy regimen of
carboplatin (AUC 6) and paclitaxel was introduced; how-
ever, radiological evaluation after three chemotherapy cycles
indicated tumor progression, and treatment was changed to
gemcitabine (single agent). Total body CT scan performed
after three cycles of gemcitabine revealed progressive disease
in the neck and lung and an occipital hypodense lesion sus-
picious for metastasis, which was not evident on a prior
brain CT. Brain MRI excluded any additional brain lesions
or direct tumor invasion to the brain (Figure 1). Biopsy from
the brain lesion indicated positive staining for in situ hybrid-
izationforEpstein-Barrvirus(EBV),whilestainingforTTF1
and P63 was negative. These results were consistent with
NPC metastasis. The patient received a total radiation dose
of 40Gy (26.6Gy per fraction) to the solitary brain lesion
using volumetric modulated arc therapy (VMAT). Nonethe-
less, soon after completion of radiotherapy, the patient’s per-
formance status continued to deteriorate due to his systemic
disease and he was oﬀered best supportive care.
3. Discussion
Despite the fact that NPC has a distinctive ethnic and geo-
graphic distribution, immigration is a common phenom-
enon, and in some cases the incidence may still be high in
immigrants and oﬀspring [1–6].
The patient presented here, a male of North African
descent, was diagnosed with extremely aggressive disease,
including brain metastasis. Israel is considered to be a low-
to-intermediate incidence area of NPC; however, the inci-
dence in North Africa is relatively higher [1, 2]. Migrant
epidemiological data showed that, even after immigration
to Israel, the high incidence of NPC persisted among North
African immigrants and their oﬀspring, compared to the
local population [1]. These results, among others, sug-
gest that both genetic and environmental factors play an
important role in the pathogenesis of NPC. This may also
explain the fact that only a minor proportion of people
infected with EBV developed NPC. Most patients diagnosed
with NPC in Israel are found to have either nonkeratinizing
carcinoma or undiﬀerentiated carcinoma and are diagnosed
at an advanced stage; both histology types are strongly as-
sociated with EBV [2, 3].Case Reports in Medicine 3
Table 1: Brain metastasis from nasopharyngeal carcinoma.
Author/year Gender/age Ethnicity Systemic




Khor et al./1978[10] 3 p a t i e n t s ?????




de Bree et al./2001 [12] Male/65 ? + ? ? ?
de Bree et al./2001 [12] Female/64 ? + lung ? ? ?
Ngan et al./2002 [8] Male/33 Chinese + lung Left occipital Undiﬀerentiated
carcinoma +
¨ Ozyar et al./2004 [11] Male/41 ? — Temporal lobe Undiﬀerentiated
carcinoma —
Present case Male/56 Israeli/North
African + lung Occipital Undiﬀerentiated
carcinoma +
∗at time of brain metastasis diagnosis.
Brain metastases of NPC are rare. A PubMed database
search revealed only a few well-described relevant cases.
Other reports of CNS involvement describe spinal or pitu-
itary metastases. This paper does not encompass reports of
spinal involvement, leptomeningeal spread, or direct intra-
cranial invasion. All the reports of brain metastases are
summarized in Table 1 [7–12]. Every patient whose clinical
information was reported had node-positive disease. Some
reports did not indicate which radiological evaluation was
undertaken to exclude direct invasion to the brain.
Liaw et al. [9] published an analysis of 352 cases of NPC
to determine the pattern of distant metastases; of these,
three were cases of CNS metastases, but no information
was given regarding whether these represent cases with a
single brain metastasis, the treatment these patients received,
or their outcomes. Kuten et al. [7] reported a case of left
occipital lobe NPC metastasis that presented 58 months
from the end of the primary radiotherapy. In this case, in
view of locally advanced disease at presentation, the patient
received induction chemotherapy consisting of four drugs.
Partial remission of the neck lymph nodes and the primary
NPC site was attained prior to deﬁnitive radiotherapy. Total
radiotherapy dose to the primary site was 62Gy, with 60Gy
totheneck;asupplementedboostwasgiventoinvolvedsites,
but the boost dose was not reported. Complete remission
was achieved, and the patient remained well for 45 months.
The patient presented in this paper had an aggressive dis-
ease and progressed early after deﬁnitive radiotherapy, as
noted by pathology-proven lung metastases.
Functional imaging is still under investigation in NPC;
however, some reports suggested that a high standardized
uptake value (SUV) on FDG-PET/CT scans has a potential
value as a prognostic indicator. High pretreatment SUV had
asigniﬁcantlylower3-yeardisease-freesurvivalthanpatients
with lower FDG uptake [13]. The patient present in this
case had evidence of advance disease in FDG-PET/CT and
relatively high pretreatment SUV count. FDG-PET/CT scan
performed three months after completion of chemo-radio-
therapy showed pathological uptakes in the left cervical
lymph nodes with an SUV of 5 (Figure 2); however, there is
L
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Figure 2: FDG-PET/CT scan performed three months after
completion of chemoradiotherapy showed pathological uptakes in
the left cervical lymph nodes.
no concrete evidence in regard to the value of posttreatment
SUV as an indicator for survival [5, 13].
Kuten et al. [7] also reported that their patient had lung
metastasis preceding the metastasis to the brain and, as in
the presented case, EBV staining using in situ hybridization
was positive. Their patient was treated with surgery and
chemotherapy for both metastasis sites but died six months
later due to the progressive metastatic lung disease. As
evidenced by both these cases, the extent and control of
the systemic disease are crucial in determining the prog-
nosis after successful treatment of brain metastases. In the
presented case, VMAT was applied for radiation of the brain
lesion after brain MRI conﬁrmed a solitary lesion. This
technique combines 3D volumetric imaging and advanced
treatment planning, thereby maximizing the radiation dose
to the target and minimizing exposure to surrounding
healthy tissues.
Another case of NPC occipital lobe metastases was re-
ported by Ngan et al. [8]. In this case the patient had4 Case Reports in Medicine
bilateral occipital lobe involvement diagnosed at presen-
tation of NPC. The patient also had blastic bone lesions
assumed to be of NPC origin after other malignancies were
excluded, including prostate cancer. Biopsy of the brain
lesion indicated squamous cell carcinoma; EBV status was
not reported. The patient was treated with systemic chemo-
therapy and head and neck radiotherapy and was reported to
be alive on palliative treatment. Khor et al. [10]r e p o r t e da
case of NPC with an isolated brain metastasis that appeared
45 months after completion of treatment, which included
chemotherapy, external radiation, and brachytherapy. The
brain lesion was assumed to be a slow infection of the mas-
toid air cells and thus was completely excised by craniotomy.
The patient was treated with whole-brain radiotherapy (total
dose of 30Gy in 10 fractions). This case is unique in that the
patient had no other sites of metastasis; moreover, the lesion
was located in the temporal lobe rather than the occipital
lobe, as reported previously.
Direct intracranial invasion to the skull base is not
uncommon in advanced NPC and considered T4 disease;
however, true brain metastases of NPC are uncommon,
perhaps due to the sanctuary of the brain. Even though cases
of spinal cord involvement were reported, these patients
did not have synchronous brain metastases. This may imply
either that metastatic spread to the brain through the CSF
was not the most common route or that patients did not
survive long enough to develop brain metastases. Another
possible explanation is that the brain is not a favorable site
for developing metastasis of NPC. It seems that, in cases of
disseminated aggressive disease, metastasis in uncommon
sites such as the brain may be encountered.
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